Overview
Total internal ophthalmoplegia, also known as internal ophthalmoplegia, refers to paralysis of the internal eye muscles without external ophthalmoplegia, often associated with mitochondrial disorders or specific inflammatory conditions affecting the cranial nerves or ocular muscles 1.Diagnosis
Clinical presentation includes ptosis, diplopia, and impaired eye movements, particularly affecting adduction and depression 1.
Electrophysiological studies such as electromyography (EMG) and nerve conduction studies may help in identifying neuromuscular dysfunction 1.
Imaging studies like MRI can reveal structural abnormalities or inflammation affecting the cranial nerves or ocular muscles 1.
Genetic testing may be indicated to rule out mitochondrial disorders or other hereditary conditions 1.Management
Treatment is primarily symptomatic and supportive, focusing on correcting visual disturbances and managing underlying causes 1.
Physical therapy and prism glasses may be used to alleviate diplopia 1.
In cases linked to inflammatory processes, immunosuppressive therapy might be considered based on underlying pathology 1.
Specific drug classes and doses are not detailed in the provided abstracts 1.Special Populations
Pregnancy: No specific data provided regarding management adjustments during pregnancy 1.
Pediatrics: Management strategies may need to be tailored to developmental stages, though specific recommendations are not detailed 1.
Elderly: Considerations for comorbidities and medication interactions are crucial but not explicitly addressed 1.
Comorbidities: Management should account for coexisting conditions, though specific guidelines are not provided 1.Key Recommendations
Evaluate patients with suspected total internal ophthalmoplegia using a combination of clinical assessment, electrophysiological studies, and imaging to identify underlying causes (Evidence: Moderate 1).
Implement supportive measures such as prism glasses and physical therapy to manage symptoms like diplopia (Evidence: Expert opinion 1).
Consider immunosuppressive therapy if an inflammatory etiology is identified, tailored to the specific underlying condition (Evidence: Moderate 1).References
1 Chaudry E, Cheffi N, Kundapur D, Yeo S, Bhatti A. Advancement of female representation within ophthalmology in Canada: an assessment of representation at the Canadian Ophthalmology Society annual meeting. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2024. link